Management of Bleeding Using Recombinant Factor VIIa in a Patient Suffering from Bleeding Tendency due to a Lupus Anticoagulant-hypoprothrombinemia Syndrome

• References

• 1 Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 1999; 93: 2149-57.
• 2 Fleck RA, Rapaport S, Rao LVM. Anti-prothrombin and the lupus anticoagulant. Blood 1988; 72: 515-9.
• 3 Diness V, Lund-Hansen T, Hedner U. Effect of recombinant human FVIIA on warfarin-induced bleeding in rats. Thromb Res 1990; 59: 921-9.
• 4 Ley AB, Reader GG, Sorenson CW, Overman RS. Idiopathic hypoprothrombinemia associated with hemorrhagic diathesis and the effect of vitamin K. Blood 1955; 10: 691-706.
• 5 Rapaport S, Ames SB, Duval BJ. A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with antiprothrombinase activity. Blood 1960; 15: 212-27.
• 6 Bajaj PS, Rapaport SI, Barclay S, Herbst KD. Aquired hypoprothrombinemia due to nonneutralizing antibodies to prothrombin: Mechanism and management. Blood 1985; 65: 1538-43.
• 7 Williams S, Linardic C, Wilson O, Comp F, Gralnick HR. Acquired hypoprothrombinemia: effets of danazol treatment. Am J Hematol 1996; 53: 272-6.
• 8 Pernod G, Arvieux J, Carpentier PH, Mossuz P, Bosson JL, Polack B. Successful treatment of lupus anticoagulant-hypoprothrombinemia syndrome using intravenous immunoglobulin. Thomb Haemost 1997; 78: 969-70.